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Objectives The purpose of this study was to understand the possible risk of discontinuation in the context of clinical care.
Background Rivaroxaban is noninferior to warfarin for preventing stroke in atrial fibrillation patients. Concerns exist regarding
possible increased risk of stroke and non–central nervous system (CNS) thromboembolic events early after dis-
continuation of rivaroxaban.
Methods We undertook a post-hoc analysis of data from the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa
Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrilla-
tion, n  14,624) for stroke or non-CNS embolism within 30 days after temporary interruptions of 3 days or
more, early permanent study drug discontinuation, and end-of-study transition to open-label therapy.
Results Stroke and non-CNS embolism occurred at similar rates after temporary interruptions (rivaroxaban: n  9, war-
farin: n  8, 6.20 vs. 5.05/100 patient-years, hazard ratio [HR]: 1.28, 95% confidence interval [CI]: 0.49 to 3.31,
p  0.62) and after early permanent discontinuation (rivaroxaban: n  42, warfarin: n  36, 25.60 vs. 23.28/
100 patient-years, HR: 1.10, 95% CI: 0.71 to 1.72, p  0.66). Patients transitioning to open-label therapy at the
end of the study had more strokes with rivaroxaban (n  22) versus warfarin (n  6, 6.42 vs. 1.73/100 patient-
years, HR: 3.72, 95% CI: 1.51 to 9.16, p  0.0044) and took longer to reach a therapeutic international normal-
ized ratio with rivaroxaban versus warfarin. All thrombotic events within 30 days of any study drug cessation (in-
cluding stroke, non-CNS embolism, myocardial infarction, and vascular death) were similar between groups (HR:
1.02, 95% CI: 0.83 to 1.26, p  0.85).
Conclusions In atrial fibrillation patients who temporarily or permanently discontinued anticoagulation, the risk of stroke or
non-CNS embolism was similar with rivaroxaban or warfarin. An increased risk of stroke and non-CNS embolism
was observed in rivaroxaban-treated patients compared with warfarin-treated patients after the end of the study,
underscoring the importance of therapeutic anticoagulation coverage during such a transition. (J Am Coll
Cardiol 2013;61:651–8) © 2013 by the American College of Cardiology Foundation
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are at increased risk for ischemic
stroke, a risk that is reduced sig-
nificantly with warfarin (1). Un-
fortunately, nearly one-quarter of
patients started on warfarin dis-
continue therapy within the first
year, either because of the chal-
lenges of monitoring, intolerabil-
ity, or adverse bleeding events
(2,3). The limitations of warfarin
illustrate the need for alternative
therapeutic options.
See page 659
Rivaroxaban is an oral direct factor Xa inhibitor with
consistent and predictable anticoagulation effects. In the
double-blind ROCKET AF (Rivaroxaban Once-Daily,
Oral, Direct Factor Xa Inhibition Compared With Vitamin
K Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation), rivaroxaban was found to be
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2012, accepted September 16, 2012.noninferior to warfarin for the prevention of stroke and
systemic embolism in patients with moderate- to high-risk
nonvalvular AF (4). The ROCKET AF findings resulted in
rivaroxaban being approved as an alternative to warfarin for
stroke prevention. However, concerns regarding a potential
increased risk of events after discontinuation led the United
States Food and Drug Administration to require a boxed
warning on the package insert stating “discontinuing rivar-
oxaban places patients at an increased risk of thrombotic
events,” and “an increased risk of stroke was observed
following rivaroxaban discontinuation in clinical trials in
atrial fibrillation patients” (5).
In an effort to understand the possible risk of discontinua-
tion in the context of clinical care, we evaluated patients who
had a temporary interruption or an early permanent study drug
discontinuation and all patients who completed the ROCKET
AF and transitioned to open-label therapy for the primary
event of stroke and non–central nervous system (CNS) embo-
lism and other thrombotic events, including myocardial infarc-
tion (MI) and death, up to 30 days after discontinuation.
Methods
The design and results of the ROCKET AF have been
reported previously (4,6). Briefly, the ROCKET AF was a
multicenter, randomized, double-blind, double-dummy,
event-driven trial comparing fixed-dose rivaroxaban (20 mg
daily or 15 mg daily in patients with creatinine clearance of
30 to 49 ml/min) with adjusted-dose warfarin (target
international normalized ratio [INR]: 2.0 to 3.0) for pre-
vention of all stroke (ischemic or hemorrhagic) or systemic
embolism (6). To be enrolled in the study, patients were
required to have nonvalvular AF and an elevated risk of
stroke as defined by a history of stroke, transient ischemic
attack, or systemic embolism or at least 2 of the following
risk factors: heart failure or left ventricular ejection fraction
of 35% or less, hypertension, age 75 years or older, or
diabetes mellitus (CHADS2 score [CHADS2 is a mne-
onic device in which 1 point is assigned for each of the
ollowing risk factors: C  Congestive heart failure, H 
Hypertension, A  age 75 yrs, D  diabetes, and S2 
points for prior Stroke or TIA]: 2). Of note for
emporary interruptions, investigators were instructed to
top the warfarin or placebo tablets 4 days before elective
rocedures and the rivaroxaban or placebo tablets 2 days
efore elective procedures.
To understand the risk of discontinuation of rivaroxaban
ompared with warfarin, we evaluated 3 clinically relevant
ituations during the ROCKET AF (Fig. 1). The first was
atients with temporary interruptions, defined as any inter-
uption of more than 3 days. These temporary interruption
atients were evaluated for clinical events that occurred
rom 3 days after study drug interruption to 3 days after
esumption of study drug. Multiple patients may have had
everal temporary interruptions. The second was patients
ith early permanent study drug discontinuation who were
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tinuation. The third was patients completing the study,
defined as receiving the study drug at site notification of
study end. These end-of-study patients underwent blinded
transition to open-label therapy, most commonly warfarin.
Patients also were followed up for events from 3 to 30 days
after the end of the study.
Outcomes and outcomes assessments. In the ROCKET
AF, a double-blind design was chosen to reduce bias in
cointerventions and to ensure adequate assessment and
reporting of clinical events both during administration of
study drug and after all study drug discontinuations. The
protocol required that all randomized patients be seen at 1,
2, and 4 weeks and monthly thereafter for the duration of
the study for measurement of INR, surveillance for primary
end point events, transient ischemic attack, MI, medical or
surgical procedures, adverse events, and vital status. Study
coordinators conducted a pill count at each visit. Personnel
at sites were trained explicitly not to record a drug inter-
ruption for dose titration or any inadvertently missed dose
or accidental interruption that was shorter than 3 days.
The primary efficacy end point was the composite of all
stroke (both ischemic and hemorrhagic) and systemic em-
bolism. Stroke was defined as a sudden focal neurologic
deficit of presumed cerebrovascular cause that persisted
beyond 24 h and was not the result of another identifiable
cause. An event matching this definition but lasting fewer
than 24 h was considered to be a transient ischemic attack.
Non-CNS systemic embolism was defined as abrupt vascu-
Figure 1 Study Flow Diagram
ROCKET AF study flow with relevant populations for analysis of interruption or disclar insufficiency associated with clinical or radiologicalevidence of arterial occlusion in the absence of another likely
mechanism (e.g., atherosclerosis, instrumentation, or
trauma). In the presence of atherosclerotic peripheral arte-
rial disease, a diagnosis of embolism required angiographic
demonstration of abrupt arterial occlusion. The major sec-
ondary efficacy end point included stroke, non-CNS embo-
lism, MI, and vascular death.
The principal safety end point was the composite of major
and nonmajor clinically relevant bleeding events. Major bleed-
ing was defined as clinically overt bleeding associated with any
of the following: fatal outcome, involvement of a critical
anatomic site (intracranial, spinal, ocular, pericardial, articular,
retroperitoneal, or intramuscular with compartment syn-
drome), fall in hemoglobin concentration of 2 g/dl or more,
transfusion of 2 units or more of whole blood or packed red
blood cells, or permanent disability. An independent clinical
end point committee adjudicated all suspected stroke, systemic
embolism, MI, vascular death, and bleeding events based on
the pre-specified end point definitions.
The study was supported by grants from Johnson &
Johnson Pharmaceutical Research & Development, Raritan,
New Jersey, and Bayer HealthCare AG, Leverkusen, Ger-
many. The Duke Clinical Research Institute, Durham,
North Carolina, coordinated the trial, managed the data-
base, and performed the primary analyses for this study,
independent of the sponsors. All appropriate national reg-
ulatory authorities and ethics committees at participating
centers approved the study. An international executive
committee, which included nonvoting representatives from
ation. EOS  end of study; VKA  vitamin K antagonist.ontinuthe sponsors, designed the trial and was responsible for
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responsibility for the accuracy and completeness of this post
hoc analysis of clinical events after discontinuations.
Statistical analysis. To evaluate the effect of interruption
or discontinuation of therapy, this post hoc analysis was
conducted in all ROCKET AF patients who received 1 dose
of study drug and were followed up for events after
temporary interruptions of 3 days or more, permanent
discontinuations, and after the end-of-study transition.
Hazard ratios (HRs) for rivaroxaban and warfarin, 95%
confidence intervals (CIs), and p values were determined
based on Cox proportional hazards models with treatment
as the only covariate. For analysis of outcomes after early
permanent discontinuation or study completion, only pa-
tients with at least 3 days of follow-up after ending study
drug treatment are included. Testing for superiority used a
2-sided significance level of 0.05.
Results
In the ROCKET AF, 14,264 patients underwent random-
ization. As previously noted, because of violations in Good
Clinical Practice making the data unreliable, 93 patients (50
Baseline Characteristics by Discontinuation Status and RandomizeTable 1 Baseline Characteristics by Discontinuation Status an
All Patients
(n  14,143)
Any Dis
Rivaroxaban
(n  4,021)
Age, yrs 73 (65, 78) 74 (66, 79)
Male 8,553 (60.5) 2,503 (62.2)
BMI, kg/m2 28.2 (25.1, 32.0) 28.2 (25.2, 32.0)
Blood pressure, mm Hg
Systolic 130 (120, 140) 130 (120, 140)
Diastolic 80 (70, 85) 80 (70, 85)
Type of atrial fibrillation
Persistent 11,462 (81.0) 3,244 (80.7)
Paroxysmal 2,487 (17.6) 726 (18.1)
Newly diagnosed or new onset 194 (1.4) 51 (1.3)
Previous medication use
Aspirin at baseline 4,098 (29.0) 1,251 (31.1)
Vitamin K antagonist 8,834 (62.5) 2,490 (61.9)
CHADS2 score
1 3 (0.1) 1 (0.1)
2 1,853 (13.1) 571 (14.2)
3 6,156 (43.5) 1,726 (42.9)
4 4,061 (28.7) 1,148 (28.6)
5 1,793 (12.7) 496 (12.3)
6 277 (2.0) 79 (2.0)
Coexisting condition
Previous stroke or TIA 7,414 (52.4) 1,976 (49.1)
Congestive heart failure 8,837 (62.5) 2,529 (62.9)
Hypertension 12,801 (90.5) 3,636 (90.4)
Diabetes 5,635 (39.8) 1,661 (41.3)
COPD 1,477 (10.4) 476 (11.8)
CrCl, ml/min† 67 (52, 87) 66 (51, 86)
Values are median (25th, 75th) or n (%). *For aggregate evaluation of any discontinuation vs. no
BMI  body mass index; CHADS2  C  Congestive heart failure, H  Hypertension, A  age 75 yrs
isease; CrCl  creatinine clearance; TIA  transient ischemic attack.in the rivaroxaban group and 43 in the warfarin group) were
excluded from the analysis. An additional 28 patients never
received study drug. After excluding these patients, 14,143
patients took at least 1 dose of study drug and were eligible
for the analysis of discontinuation. During the 590 days of
median treatment exposure, 8,245 temporary interruptions
occurred (3,734 in the rivaroxaban group and 4,511 in the
warfarin group). Early permanent discontinuation occurred
in 4,895 (2,470 in the rivaroxaban group and 2,425 in the
warfarin group). Completion of the study without an
investigator-suspected primary end point event, death, or
early permanent discontinuation occurred in 9,239 patients
(4,587 in the rivaroxaban group and 4,652 in the warfarin
group).
Patient characteristics. Key clinical characteristics of pa-
tients who received study drug and had any type of discon-
tinuation (n  8,261 [rivaroxaban: 4,021, warfarin: 4,240])
compared with patients who did not have any discontinu-
ation (n  5,882 [rivaroxaban: 3,040, warfarin: 2,842]) are
shown in Table 1. In general, patients in both groups were
similar with regard to age (median age: 73 years), sex (more
than 60% male), and risk factors for stroke. Patients
atmentdomized Treatment
uation No Discontinuation
p Value*
Warfarin
(n  4,240)
Rivaroxaban
(n  3,040)
Warfarin
(n  2,842)
73 (66, 78) 72 (64, 77) 71 (64, 77) 0.0001
2,549 (60.1) 1,767 (58.1) 1,734 (61.0) 0.050
28.0 (25.1, 31.7) 28.4 (25.1, 32.2) 28.1 (25.1, 31.9) 0.28
130 (120, 140) 130 (120, 140) 130 (120, 140) 0.017
80 (70, 85) 80 (72, 86) 80 (72, 86) 0.0001
0.23
3,412 (80.5) 2,495 (82.1) 2,311 (81.3)
764 (18.0) 502 (16.5) 495 (17.4)
64 (1.5) 43 (1.4) 36 (1.3)
1,291 (30.4) 779 (25.6) 777 (27.3) 0.0001
2,617 (61.7) 1,910 (62.8) 1,817 (63.9) 0.062
0.0001
2 (0.1) 0 (0.0) 0 (0.0)
602 (14.2) 351 (11.5) 329 (11.6)
1,834 (43.3) 1,299 (42.7) 1,297 (45.6)
1,156 (27.3) 925 (30.4) 832 (29.3)
545 (12.9) 422 (13.9) 330 (11.6)
101 (2.4) 43 (1.4) 54 (1.9)
2,088 (49.2) 1,746 (57.4) 1,604 (56.4) 0.0001
2,675 (63.1) 1,899 (62.5) 1,734 (61.0) 0.14
3,890 (91.7) 2,736 (90.0) 2,539 (89.3) 0.0044
1,734 (40.9) 1,181 (38.8) 1,059 (37.3) 0.0003
532 (12.6) 268 (8.8) 201 (7.1) 0.0001
65 (50, 84) 70 (54, 90) 70 (55, 90) 0.0001
inuation. †Creatinine clearance was calculated using the Cockcroft-Gault formula.d Tred Ran
contin
discont
, D  diabetes, and S2  2 points for prior Stroke or TIA; COPD  chronic obstructive pulmonary
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February 12, 2013:651–8 Outcomes of Discontinuing Rivaroxaban in the ROCKET AF Trialdiscontinuing therapy were more likely to be treated with
aspirin at baseline compared with those completing the
study (30.8% vs. 26.5%, p  0.0001). Patient characteristics
for those undergoing early permanent discontinuation and
those completing the study and transitioning to open-label
therapy are presented in Online Table 1.
Discontinuation reasons and post-discontinuation therapy.
The most common reasons for early permanent study drug
discontinuation included adverse events (39%), both non-
bleeding and bleeding (Online Table 2). Additionally,
investigators were instructed to stop study drug permanently
when a primary end point was suspected, which occurred in
12.9% (n  632) of discontinuations. It should be noted
hat when these patients did not meet blinded adjudication
riteria for stroke or systemic embolism, they were followed
p for subsequent evidence of the primary end points (stroke
r systemic embolism). These events occurred and met
djudication criteria in 53 patients (rivaroxaban: n  30,
arfarin: n  23). A substantial number of all discontinu-
tions occurred when patients withdrew consent (27.4%, n 
,343) or had study drug stopped based on investigator
ecision (7.4%, n  364).
The most common reasons for temporary interruption
ere surgical or invasive procedures (38.2%) and adverse
vents (40.2%), both bleeding and nonbleeding. Review of
rocedures performed within 30 days before interruption
howed a low rate of cardiovascular procedures such as
ercutaneous coronary intervention and coronary artery
ypass graft surgery (Online Table 3). The median duration
or all temporary interruptions was 6 days.
A vitamin K antagonist was used in patients undergoing
n early permanent discontinuation in 44.3% of rivaroxaban-
reated patients and in 43.1% of warfarin-treated patients. In
atients completing the study, a vitamin K antagonist was
sed in 92.3% of rivaroxaban-treated patients and in 92.4%
f warfarin-treated patients (Table 2). As previously noted,
ore than 60% of warfarin-treated patients completing the
tudy had a therapeutic INR (2.0 to 3.0) at the first
rotocol-allowed check at 3 days, whereas less than 50% of
ivaroxaban-treated patients transitioning to open-label vi-
amin K antagonist therapy had a therapeutic INR (2.0 to
Transitions to Open-Label Vitamin K Antagonist or Aspirin Within30 Days After Study Drug Early Study Drug Disc ntinuation and StTable 2 Transitions to Open-Label Vitamin K Antago ist or Asp30 Days After Study Drug Early Study Drug Discontinu
All Patients
Rivaroxaban
(n  7,061)
Warfarin
(n  7,082)
Transition to open-label VKA 5,332 (75.5) 5,345 (75.5)
VKA type
Warfarin 4,091 (57.9) 4,082 (57.6)
Other VKA 1,241 (17.6) 1,263 (17.8)
None 1,729 (24.5) 1,737 (24.5)
Aspirin 210 (3.0) 179 (2.5)
Values are n (%). *Includes all safety patients (n  14,143).
VKA  vitamin K antagonist..0) at 30 days (Fig. 2) (4).troke or non-CNS embolism outcomes. Stroke and
on-CNS embolism occurred at similar rates after tempo-
ary interruptions (rivaroxaban: n 9, warfarin: n 8, 6.20
s. 5.05 per 100 patient-years, HR: 1.28, 95% CI: 0.49 to
.31, p  0.62) and after early permanent discontinuation
rivaroxaban: n  42, warfarin: n  36, 25.60 vs. 23.28 per
00 patient-years, HR: 1.10, 95% CI: 0.71 to 1.72, p 
.66) (Table 3). When stroke or non-CNS embolisms for
ny temporary interruption or permanent discontinuation of
tudy drug were evaluated in aggregate up to study comple-
ion, the rates also were similar between rivaroxaban- and
arfarin-treated patients (rivaroxaban: n 51, warfarin: n 44,
6.49 vs. 14.05 events per 100 patient-years, HR: 1.21, 95%
I: 0.81 to 1.81, p  0.35). Finally, when events occurring
fter permanent discontinuation for suspected stroke or
on-CNS embolism were censored, the rates remained
imilar between rivaroxaban- and warfarin-treated patients
rivaroxaban: n  12, warfarin: n  13, 8.12 vs. 9.14 events
er 100 patient-years, HR: 0.86, 95% CI: 0.39 to 1.89, p 
.71).
Significantly more strokes occurred in rivaroxaban-
reated patients (n  22) compared with warfarin-treated
atients (n  6) after the end-of-study transition from
blinded study drug to open-label warfarin (6.42 vs. 1.73 per
100 patient-years, HR: 3.72, 95% CI: 1.51 to 9.16, p 
.0044). When all discontinuations and interruptions before
tudy end were added to events after the end-of-study
ransition, there were significantly more primary events with
ivaroxaban (n  73) compared with warfarin (n 50, HR:
1.20 vs. 7.57 per 100 patient-years, HR: 1.50, 95% CI:
.05 to 2.15, p  0.026) (Table 3).
ggregate thrombotic outcome events. When all throm-
otic events (the major secondary efficacy end point of the
rial)—defined as stroke, non-CNS embolism, MI, and
ascular death—were evaluated, there were similar rates
fter temporary interruptions (14 with rivaroxaban and 17
ith warfarin, 9.66 vs. 10.75 per 100 patient-years, HR:
.95, 95% CI: 0.47 to 1.94, p  0.89) and early permanent
discontinuations (131 with rivaroxaban and 147 with war-
farin, 80.01 vs. 95.28 per 100 patient-years, HR: 0.84, 95%
CI: 0.67 to 1.01, p  0.16) (Table 3). After the end of the
ompletion*ithin
and Study Completion*
Early Discontinuation Completed
varoxaban
 2,470)
Warfarin
(n  2,425)
Rivaroxaban
(n  4,591)
Warfarin
(n  4,657)
095 (44.3) 1,044 (43.1) 4,237 (92.3) 4,301 (92.4)
853 (34.5) 822 (33.9) 3,238 (70.5) 3,260 (70.0)
242 (9.8) 222 (9.2) 999 (21.8) 1,041 (22.4)
375 (55.7) 1,381 (56.9) 354 (7.7) 356 (7.6)
128 (5.2) 112 (4.6) 82 (1.8) 67 (1.4)udy Cirin W
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Ri
(n
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1,study, there were significantly more thrombotic events with
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Outcomes of Discontinuing Rivaroxaban in the ROCKET AF Trial February 12, 2013:651–8rivaroxaban (n  31) compared with warfarin (n  14, 9.05
s. 4.03 per 100 patient-years, HR: 2.24, 95% CI: 1.19 to
.22, p  0.012). When all discontinuations and interrup-
ions before the study end and end-of-study events were
valuated in aggregate, there was no significant difference
etween rivaroxaban and warfarin (HR: 1.02, 95% CI: 0.83
o 1.36, p  0.85).
ajor bleeding. The rates of major bleeding were similar
fter temporary interruptions (24 with rivaroxaban and 27
ith warfarin, 16.66 vs. 17.20 per 100 patient-years, HR:
.02, 95% CI: 0.59 to 1.77, p  0.94) and after early
ermanent discontinuation (21 with rivaroxaban and 33
ith warfarin, 12.71 vs. 21.29 per 100 patient-years, HR:
.60, 95% CI: 0.35 to 1.04, p  0.067) (Table 4). Signifi-
antly more major bleeding events were observed after the
nd of the study during the transition period in rivaroxaban-
reated subjects compared with warfarin-treated subjects (25
ith rivaroxaban and 7 with warfarin, 7.29 vs. 2.01 per 100
atient-years, HR: 3.62, 95% CI: 1.56 to 8.36, p 0.0026).
gain, there was no significant difference when all discon-
Stroke or Non–Central Nervous System Embolism Rates and StrokeMy cardial I farction, or Vascular D ath During Post–Study-Drug DTable 3 Stroke or Non–Central Nervous Sy tem Embolism RatMyocardial Infarction, or Vascular Death During Post–S
Ri
Stroke or non-CNS embolism rates
All discontinuations and interruptions (before end of study) 16
Temporary interruptions 6
Permanent discontinuations 25
After end of study 6
All discontinuations and interruptions (before end of study)  after
end of study events
11
Stroke, non-CNS embolism, MI, or vascular death
All discontinuations and interruptions (before end of study) 46
Temporary interruptions 9
Permanent discontinuations 80
After end of study 9
All discontinuations and interruptions (before end of study)  after
end of study events
27
*Risk period for temporary interruptions is 3 days post-stop to 3 days post-resumption; for perma
of study, only patients with 3 days follow-up post-stop are included (N13,650).
CI  confidence interval; CNS  central nervous system; HR  hazard ratio; MI  myocardial i
Discontinuation Events: Major Bleeding Occurring During Post–StuTable 4 Discontinuation Events: Major Bleeding Occurring Duri
Riva
All discontinuations and interruptions (before end of study) 14
Temporary interruptions 16
Permanent discontinuations 12
After end of study 7
All discontinuations and interruptions (before end of study) 
after end-of-study events
10
*Risk period for temporary interruptions is 3 days after stopping to 3 days after resumption. Th
discontinuations and end of study, only patients with 3 days or more of follow-up after stopping are inclu
Abbreviations as in Table 3.inuations and interruptions before completion and end-of-
tudy major bleeds were evaluated in aggregate (70 with
ivaroxaban and 67 with warfarin, 10.74 vs. 10.16 per 100
atient-years, HR: 1.07, 95% CI: 0.77 to 1.50, p  0.67).
iscussion
his analysis of clinical events occurring after temporary
nterruptions, early permanent discontinuations, or end-of-
tudy transition from study drug during the ROCKET AF
rovides several critical insights for clinicians considering
he use of anticoagulants in AF patients at moderate to high
isk of stroke. The most important finding in this analysis is
hat there were no significant differences between rivaroxa-
an and warfarin in the rates of stroke or non-CNS
mbolism after temporary interruption or early permanent
iscontinuation, when both blinded therapies were stopped.
fter the end of the study and after mandatory withdrawal
f blinded study drug, when patients treated with rivaroxa-
an frequently were transitioned to open-label vitamin K
n–Central Nervous System Embolism,tinuation Risk Period*Stroke, Non–Central Nervous Sy tem Embolism,
-Drug Discontinuation Risk Period*
ts per 100 Patient-Yrs
(Total Events)
Rivaroxaban:
Warfarin HR (95% CI) p Valueban Warfarin
1) 14.05 (44) 1.21 (0.81–1.81) 0.35
) 5.05 (8) 1.28 (0.49–3.31) 0.62
2) 23.28 (36) 1.10 (0.71–1.72) 0.66
2) 1.73 (6) 3.72 (1.51–9.16) 0.0044
3) 7.57 (50) 1.50 (1.05–2.15) 0.026
45) 52.50 (164) 0.92 (0.74–1.15) 0.47
4) 10.75 (17) 0.95 (0.47–1.94) 0.89
31) 95.28 (147) 0.84 (0.67–1.07) 0.16
1) 4.03 (14) 2.24 (1.19–4.22) 0.012
76) 26.97 (178) 1.02 (0.83–1.26) 0.85
scontinuations and end of study is 3–30 days post-stop; for permanent discontinuations and end
n.
ug Discontinuation Risk Period*st–Study-Drug Discontinuation Risk Period*
s per 100 Patient-Yrs
(Total Events)
Rivaroxaban:
Warfarin HR (95% CI) p Valuean Warfarin
) 19.23 (60) 0.79 (0.54–1.16) 0.23
) 17.20 (27) 1.02 (0.59–1.77) 0.94
) 21.29 (33) 0.60 (0.35–1.04) 0.067
) 2.01 (7) 3.62 (1.56–8.36) 0.0026
) 10.16 (67) 1.07 (0.77–1.50) 0.67
ermanent discontinuations and end of study is 3 to 30 days after stopping. That for permanent, Noiscons and
tudy
Even
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February 12, 2013:651–8 Outcomes of Discontinuing Rivaroxaban in the ROCKET AF Trialantagonists and patients treated with warfarin were contin-
ued on vitamin K antagonist prophylaxis, there were signif-
icantly more strokes and non-CNS embolism events in
patients who had received rivaroxaban compared with those
who had received warfarin. Finally, when all thrombotic
events that included stroke, non-CNS embolism, MI, and
vascular death were evaluated for interruptions and discon-
tinuation both during and after the study, there was no
significant difference between rivaroxaban and warfarin.
Review of the events after withdrawal of therapy, both
during and after the trial, provides important implications
regarding the existing box warning and provides lessons for
the current clinical use of rivaroxaban and warfarin. Con-
sistent with the moderate- to high-risk elderly population
enrolled in the ROCKET AF, temporary interruptions
were frequent in both groups. Surgical and invasive proce-
dures were the most common reasons for temporary inter-
ruptions, and the median duration of a temporary interrup-
tion was 6 days. Although there were few strokes (9 with
rivaroxaban and 8 with warfarin), given the large number of
short interruptions in a trial of this size, the rate of stroke
and systemic embolism observed provides an important
observation for physicians and patients considering inter-
ruption. The rate of stroke and systemic embolism observed
was similar between therapies and likely represents the
intrinsic stroke rate for patients at moderate to high risk
who are without therapeutic anticoagulation. Stated another
way, even with short temporary interruptions, the protec-
tion from anticoagulant therapy for AF is lost and the
baseline patient risk becomes evident when observed over
several thousand interruptions. These findings draw atten-
tion to the potential value of adequate anticoagulation
coverage during interruptions, an aim of ongoing studies
(7), and the importance of minimizing interruptions.
Patients undergoing early permanent study drug discon-
tinuation had high rates of both stroke and systemic
embolism and all thrombotic events within 30 days of
cessation of therapy. To understand the high observed event
rates, it is important to recognize that this group represents
a unique set of patients during the conduct of the clinical
trial. These patients often had adverse events (both bleeding
and nonbleeding) before permanent study discontinuation
and were deemed high risk by study investigators for
continued anticoagulation, as evidenced by less than 50%
receiving vitamin K antagonists within the first 30 days after
permanent discontinuation of study drug. These findings
underscore the complex interplay between bleeding and
thrombosis and the difficulty in managing moderate- to
high-risk AF patients unable to tolerate anticoagulation
therapy. Additionally, most of the events in patients under-
going permanent discontinuation (n  53) occurred in
patients whose local physician or investigator suspected a
stroke or non-CNS embolism. This finding highlights
patients with transient ischemic attacks and possible stut-
tering neurologic clinical events that led to permanent
discontinuation and recurrent events within 30 days, asmight have been expected. This is consistent with the
findings of prior studies in patients with suspected stroke,
which indicated that the interruption of anticoagulation
increases the risk of subsequent thrombotic events (8,9).
Hence, these findings draw attention to the importance of
anticoagulation coverage and decisions for patients having
adverse events, specifically patients with suspected embolic
events. Despite all of these complexities, we found that
patients with early permanent study drug discontinuation
had similar rates of stroke, systemic embolism, and all
thrombotic events when treated with rivaroxaban compared
with those treated with warfarin.
Patients completing the study and transitioning to open-
label prophylaxis, most often vitamin K antagonists, repre-
sent 2 distinct populations. The patients who transitioned
from rivaroxaban to warfarin had a period of transition
consistent with prolonged time to a therapeutic INR (Fig. 2). In
this sense, these patients were similar to those with tempo-
rary interruptions, where anticoagulation coverage was not
present. In fact, the observation of similar stroke rates
(approximately 6 per 100 patient-years) between these 2
groups highlights this similar and likely intrinsic risk for
moderate- to high-risk AF patients. Unlike the rivaroxaban
patients who had poor coverage through the transition, the
warfarin group continued to receive vitamin K antagonist
prophylaxis and had no uncovered period, as evidenced by
the time to a therapeutic INR (3 days), the first time
investigators were permitted to check an unblinded INR at
the end of the study. This observed event rate of fewer than
2 per 100 patient-years is consistent with the rate that may
be expected in patients completing the study and is similar
to the on-treatment event rate in the overall trial.
In aggregate, these data have several implications. Re-
garding the existing box warning, there is in fact a numer-
Figure 2 Time to Therapeutic International Normalized Ratio
Cumulative proportion of patients with international normalized ratio (INR) of 2
or more after the end of the study for those treated with warfarin and rivaroxa-
ban during the ROCKET AF study.ically increased thrombotic risk with discontinuation of
1w
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was statistically similar when compared with discontinua-
tion of warfarin. The hazard seen during the post-clinical
trial transition from rivaroxaban to warfarin drives the excess
strokes seen after all interruptions and discontinuations.
Further research is needed to understand how to manage
these patients best. Additionally, from a study methodology
perspective, post-study transition events and therapy post-
discontinuation should be collected and reported for
clinical trials evaluating anticoagulants to help inform
these decisions.
Several findings should inform current clinical practice.
First, both clinicians and patients should be aware of the
significant risk of stroke, non-CNS embolism, and throm-
botic events when anticoagulation, including rivaroxaban or
warfarin, is stopped on either a temporary or permanent
basis. For the temporary interruptions, these findings sup-
port careful assessment of continued anticoagulation cover-
age in these moderate- to high-risk AF patients, where the
intrinsic stroke or non-CNS embolism rate may be approx-
imately 6 per 100 patient-years (10). Whether bridging
anticoagulation will produce net clinical benefit is unclear,
but it seems wise to minimize the period of discontinuation.
Additionally, these findings argue for careful attention in
ensuring timely anticoagulation coverage if patients are
transitioned from rivaroxaban to warfarin. It should be
noted that there is not a known mechanism for a prothrom-
botic state during this transition. This may not be a
common occurrence in clinical practice, but should be
considered carefully if needed.
This study is limited by the observational nature of the
analysis. Additionally, there may be unmeasured confound-
ers that are associated with discontinuation. However, the
blinded nature of the study should provide reassurance
regarding decisions to discontinue therapies. Finally, al-
though the current analysis is limited by the lack of detailed
information regarding medical therapy after discontinua-
tion, available data on the use of vitamin K antagonists
demonstrate high rates of use for patients completing the
study.
Conclusions
In moderate- to high-risk AF patients temporarily inter-
rupting or permanently discontinuing anticoagulation, the
risk of stroke or systemic embolism was similar when they
were treated with rivaroxaban or warfarin. After the end-
of-study transition to warfarin, an increased risk of stroke
and systemic embolism was observed for patients being
treated with rivaroxaban compared with those treated withwarfarin, underscoring the importance of expeditious anti-
coagulation coverage during the transition from one anti-
thrombotic therapy to another.
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